Prior to this IHL-42X Trial, t
he issue with using dronabinol as a treatment for sleep apnoea is that it still displayed some level of impairment in the patient because as you are aware dronabinol is a synthetic form of THC.The challenge for Incannex was to create a formulation in IHL-42X that achieved the two goals> Reduce the level of severity of OSA in patients and> Reduce the amount of dronabinol so as to fix the breathing issuesbut not give the patient so much (dronabinol) to prevent them from driving or operating and function normally the next day.The Phase2 Trial has been dosing patients to find the optimal dosage to achieve these goals.
Now we can prove to the world that we have a Super Charged Therapy for Sleep Apnoea
•
IHL-42X was observed to be well tolerated in the clinical trial• IHL-42X has the potential to reduce disease severity, resulting in improved sleep quality,
multiple major health benefits and increased quality of life
Being
Well Tolerated is massive because before this study Dronabinol was not tolerable and did not allow people to function normally ie go to work the next day and function properly.
I also agree with
@Badvet73 's assessment of the BOD keeping their cards close to their chest, for the moment and not wanting to reveal commercially sensitive information too soon, to the whole world. I am comfortable knowing that 10 participants is sufficient for scientific validation with this cross-over study as per
@moguns post ......
this also helps explain the true sample size as it was much larger than 10. The reason being that each participant received:1x dose placebo1x dose low active drug1x dose med active drug1x dose high active drugEach dose was administered over a 7 day period with 1 week washout periods. 10 participants x4 doses = 40, essentially 4x groups of 10.I think some poster's concerns about the trial outcome or trial design have been explained by some experienced posters here that have some sense of the science, such as @moguns,
@MickeyMantle536 ,
@comincon,
@Oldpa1,
@tretchikoff .
Just let this soak in folks
80% of trial participants experienced a reduction in AHI levels of greater than 55% to 91.5% during at least one treatment compared to baseline.
Have a great weekend in full knowledge the company's value has increased but not yet reflected in the SP ATM !
